# GlycoEra funding rounds and investors

As of 14 Oct 2026, GlycoEra has raised $130M across 1 verified round on record; latest: $130 million Series B led by Novo Holdings, announced 27 May 2025.

Biologics aimed at precision immunology, targeting and degrading specific proteins associated with autoimmune diseases for improved patient outcomes.

Website: https://glycoera.com  
Headquarters: Wädenswil, Switzerland  
Page: https://fireround.dev/companies/glycoera.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-05-27 | Series B | $130 million | Novo Holdings | 5AM Ventures, Agent Capital, Bristol‑Myers Squibb, Catalio Capital Management, LifeArc Ventures, MP Healthcare Venture Management, QIA, Roche Venture Fund, Sixty Degree Capital, Sofinnova Partners | [glycoera.com](https://www.glycoera.com/2025/05/glycoera-ag-raises-130-million-to-advance-novel-pipeline-of-extracellular-protein-degraders-for-the-treatment-of-autoimmune-diseases), [globenewswire.com](https://www.globenewswire.com/news-release/2025/05/27/3088461/0/en/glycoera-ag-raises-130-million-to-advance-novel-pipeline-of-extracellular-protein-degraders-for-the-treatment-of-autoimmune-diseases.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.